GlaxoSmithKline, the UK-based pharmaceutical group, plans to relaunch discussions with the Department of Health in an effort to reverse a decision that the National Health Service will not adopt its new cancer medicine Tyverb.

The company has been developing a pioneering “price-volume” deal designed to overcome concerns by the government’s medicines advisory body that Tyverb is too costly for the benefit it provides to patients.